Get the Stockscreener App
26.43
1.26%
0.33
After Hours:
26.35
-0.08
-0.30%
Overview
News
Price History
Option Chain
Financials
Why PFE Down?
Discussions
Forecast
Stock Split
Dividend History
Pfizer Inc stock is traded at $26.43, with a volume of 47.31M.
It is up +1.26% in the last 24 hours and down -0.34% over the past month.
Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding covid-19-related product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.
See More
Previous Close:
$26.10
Open:
$26.055
24h Volume:
47.31M
Relative Volume:
1.26
Market Cap:
$149.78B
Revenue:
$63.63B
Net Income/Loss:
$8.03B
P/E Ratio:
18.74
EPS:
1.41
Net Cash Flow:
$9.84B
1W Performance:
+0.49%
1M Performance:
-0.34%
6M Performance:
-8.89%
1Y Performance:
-0.49%
1-Day Range:
$25.91
$26.49
1-Week Range:
$25.88
$27.03
52-Week Range:
$24.48
$31.54
Pfizer Inc Stock (PFE) Company Profile
Name
Pfizer Inc
Sector
Industry
Phone
(212) 733-2323
Address
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Compare PFE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
26.43 | 149.78B | 63.63B | 8.03B | 9.84B | 1.41 |
|
LLY
Lilly Eli Co
|
920.63 | 874.97B | 45.04B | 10.59B | 414.30M | 11.71 |
|
NVO
Novo Nordisk Adr
|
90.65 | 402.40B | 42.09B | 14.65B | 10.11B | 3.2833 |
|
ABBV
Abbvie Inc
|
209.03 | 369.01B | 56.33B | 4.28B | 17.83B | 2.40 |
|
JNJ
Johnson Johnson
|
165.02 | 344.63B | 88.82B | 14.07B | 18.06B | 5.79 |
|
MRK
Merck Co Inc
|
92.25 | 251.88B | 64.17B | 17.12B | 18.10B | 6.73 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Nov-15-24 | Initiated | Wolfe Research | Underperform |
| Oct-25-24 | Resumed | Citigroup | Neutral |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Aug-07-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Mar-22-24 | Downgrade | Argus | Buy → Hold |
| Feb-23-24 | Initiated | Guggenheim | Buy |
| Jan-04-24 | Downgrade | TD Cowen | Outperform → Market Perform |
| Oct-20-23 | Resumed | UBS | Neutral |
| Oct-16-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-17-23 | Reiterated | JP Morgan | Neutral |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Jun-29-23 | Downgrade | Credit Suisse | Outperform → Neutral |
| May-11-23 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-07-23 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Jan-26-23 | Downgrade | UBS | Buy → Neutral |
| Jan-17-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-04-23 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-13-22 | Upgrade | Goldman | Neutral → Buy |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Apr-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-05-22 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-20-21 | Reiterated | Cowen | Outperform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-13-21 | Upgrade | UBS | Neutral → Buy |
| Dec-09-21 | Initiated | Wells Fargo | Overweight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Jul-27-21 | Resumed | Truist | Buy |
| May-06-21 | Downgrade | Mizuho | Buy → Neutral |
| Apr-07-21 | Resumed | RBC Capital Mkts | Sector Perform |
| Feb-04-21 | Upgrade | DZ Bank | Hold → Buy |
| Dec-16-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-19-20 | Resumed | Goldman | Neutral |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Oct-12-20 | Downgrade | Atlantic Equities | Overweight → Neutral |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jun-16-20 | Initiated | SVB Leerink | Mkt Perform |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-27-20 | Upgrade | Standpoint Research | Hold → Buy |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Jan-07-20 | Initiated | RBC Capital Mkts | Outperform |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Jul-30-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| Jul-30-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-04-19 | Resumed | Morgan Stanley | Overweight |
| Feb-20-19 | Resumed | Citigroup | Neutral |
| Jan-31-19 | Upgrade | Argus | Hold → Buy |
| Jan-31-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| Jan-23-19 | Downgrade | UBS | Buy → Neutral |
| Dec-11-18 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-01-18 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
View All
Pfizer Inc Stock (PFE) Latest News
Is Pfizer Inc. (PFE) the Best Weight Loss Drug Stock to Buy According to Analysts? - Yahoo Finance UK
2 Top Stocks Beaten Down Near 52-Week Lows That Look Like Bargains Now - The Motley Fool
Is Pfizer Inc. (PFE) the Best Affordable Dividend Stock to Buy According to Hedge Funds? - Insider Monkey
Chase Investment Counsel Corp Trims Stock Position in Pfizer Inc. (NYSE:PFE) - MarketBeat
US Bancorp DE Sells 491,587 Shares of Pfizer Inc. (NYSE:PFE) - MarketBeat
Fisher Asset Management LLC Buys 4,938,209 Shares of Pfizer Inc. (NYSE:PFE) - MarketBeat
SVB Wealth LLC Invests $13.87 Million in Pfizer Inc. (NYSE:PFE) - MarketBeat
Mutual of America Capital Management LLC Reduces Stock Position in Pfizer Inc. (NYSE:PFE) - MarketBeat
Pfizer Inc. (NYSE:PFE) Shares Sold by Private Trust Co. NA - MarketBeat
Pfizer Inc. (NYSE:PFE) Stake Lowered by NewEdge Wealth LLC - MarketBeat
Pfizer Inc. (NYSE:PFE) Shares Sold by Oppenheimer Asset Management Inc. - MarketBeat
What is Zacks Research's Estimate for Pfizer Q3 Earnings? - MarketBeat
Blackhawk Capital Partners LLC. Sells 9,930 Shares of Pfizer Inc. (NYSE:PFE) - MarketBeat
Impax Asset Management Group plc Makes New $713,000 Investment in Pfizer Inc. (NYSE:PFE) - MarketBeat
National Pension Service Has $314.54 Million Stock Position in Pfizer Inc. (NYSE:PFE) - MarketBeat
Pfizer Inc. (NYSE:PFE) Shares Sold by Sabal Trust CO - MarketBeat
Commonwealth Retirement Investments LLC Lowers Holdings in Pfizer Inc. (NYSE:PFE) - MarketBeat
Bank of New York Mellon Corp Has $1.06 Billion Stock Position in Pfizer Inc. (NYSE:PFE) - MarketBeat
Delta Financial Advisors LLC Decreases Stock Position in Pfizer Inc. (NYSE:PFE) - MarketBeat
Amalgamated Bank Sells 28,055 Shares of Pfizer Inc. (NYSE:PFE) - MarketBeat
Pfizer (NYSE:PFE) Stock Price Down 0.4%What's Next? - MarketBeat
Former CDER Director Patrizia Cavazzoni named Pfizer chief medical officer, executive vice president - The Cancer Letter
Why Pfizer Inc. (PFE) is the Best Vaccine Stock to Buy According to Hedge Funds? - Insider Monkey
Pfizer quietly made some big DEI changes - Yahoo Finance
Covid Products Drove Pfizer's Fourth Quarter. Is It Now A Buy? - Investor's Business Daily
What’s next after Pfizer’s gene therapy for hemophilia B is halted? - Hemophilia News Today
Pfizer discontinues hemophilia B treatment Beqvez - Hemophilia News Today
EMA's CHMP Adopts Indication Extension For Abrysvo To Include Adults From 18 Years - Marketscreener.com
Turbulence at the FDA & bluebird Bio’s sale - STAT
Pfizer Drops Approved Hemophilia B Gene Therapy - MD Magazine
Pfizer is latest Big Pharma to overhaul DEI goals after GSK - Seeking Alpha
Pfizer Updates DEI Webpage to Focus on Merit -February 28, 2025 at 06:50 am EST - Marketscreener.com
Market Still Lacking Some Conviction On Pfizer Inc. (NYSE:PFE) - Simply Wall St
Spinal Cord Injury Therapeutics Market Projected To Witness Substantial Growth, 2025-2032: AbbVie Inc, Pfizer - EIN News
Is Pfizer Inc. (PFE) the Best Retirement Stock to Buy According to Hedge Funds? - Insider Monkey
Pfizer’s bet on gene therapies in haemophilia has been a bust - Yahoo Finance
Is Pfizer Inc. (PFE) the Best Stock Under $50 to Buy Right Now? - Insider Monkey
Trump Team Weighs Pulling Funds for Moderna Bird Flu Vaccine - Yahoo Finance
Activist Starboard Trailed Peers With Less Than 5% Returns - MSN
INVESTIGATION ALERT: Berger Montague PC Investigates Pfizer Inc.'s Board Of Directors For Breach of Fiduciary Duties (PFE) - TradingView
Fast Melt Tablets Market Detailed In New Research Report 2025 | Pfizer Inc., GlaxoSmithKline plc, Johnson & Johnson - openPR
Megyn Kelly claims Pfizer COVID vaccine left her with autoimmune condition: ‘Wish I hadn’t done it’ - New York Post
The Escalator: Pfizer, GSK, LiveWorld and more - MM+M Online
Haleon PLC Announces Shareholder Structure Change with Pfizer’s Conversion - TipRanks
Incretin Mimetics Market Deep Research and Growth by 2032: AstraZeneca, Pfizer Inc, Bristol-Myers Squibb Company, - openPR
Minoxidil Market Size, Industry Growth, Share & Analysis - openPR
Bernstein cuts Pfizer stock target to $30, keeps Market Perform By Investing.com - Investing.com South Africa
Bernstein cuts Pfizer stock target to $30, keeps Market Perform - Investing.com India
Haleon PLC Announces Board Change Following Pfizer Shareholding Reduction - TipRanks
Haleon announces board change as Pfizer reduces stake - Investing.com
Summit Incurs In-Line Q4 Loss, Inks Collaboration Deal With Pfizer - Nasdaq
Pfizer Inc Stock (PFE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Pfizer Inc Stock (PFE) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| DAMICO JENNIFER B. | SVP & Controller |
Feb 22 '25 |
Option Exercise |
30.17 |
8,741 |
263,716 |
17,602 |
| BOURLA ALBERT | Chairman & CEO |
Feb 22 '25 |
Option Exercise |
30.17 |
238,399 |
7,192,498 |
570,436 |
| LANKLER DOUGLAS M | Executive Vice President |
Feb 22 '25 |
Option Exercise |
30.17 |
85,824 |
2,589,310 |
232,775 |
| SAHNI PAYAL | Executive Vice President |
Feb 22 '25 |
Option Exercise |
30.17 |
12,714 |
383,581 |
37,099 |
| SUSMAN SALLY | Executive Vice President |
Feb 22 '25 |
Option Exercise |
30.17 |
63,573 |
1,917,997 |
225,184 |
| BOSHOFF CHRISTOFFEL | President, R&D |
Feb 22 '25 |
Option Exercise |
30.17 |
8,741 |
263,716 |
159,085 |
| BLAYLOCK RONALD E | Director |
Feb 13 '25 |
Buy |
25.65 |
19,457 |
499,072 |
27,707 |
| Gottlieb Scott | Director |
Oct 30 '24 |
Buy |
28.24 |
1,000 |
28,240 |
10,000 |
| DAMICO JENNIFER B. | SVP & Controller |
Aug 13 '24 |
Sale |
28.66 |
5,154 |
147,714 |
8,582 |
2.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):